HOME >> BIOLOGY >> NEWS
New antimalarial combination confirms its potential use in treating drug-resistant malaria

three-day treatment period; and a second study will compare CDA to Lapdap alone. If the development of CDA is successful, it is expected to be available in 2008 as a convenient, once-daily dose. CDA will be made available to the public sector of malaria-endemic countries at preferential prices in order to maximise its availability to those in need.

CDA is being developed in collaboration with GlaxoSmithKline (GSK), the World Health Organization's Special Programme for Research and Training in Tropical Diseases (WHO/TDR), Medicines for Malaria Venture (MMV), the University of Liverpool, Liverpool School of Tropical Medicine and the London School of Hygiene & Tropical Medicine.

Dr. Robert Ridley, Director of WHO/TDR, stated, "The collaboration between WHO/TDR, MMV, GSK and our academic partners has enabled us to combine resources and expertise to speed the development of CDA."

"GSK is committed to research and development into treatments for diseases of the developing world," said Dr. Lynn Marks, Senior Vice President, Infectious Diseases Medicine Development Centre for GSK. "Public-private partnerships, such as this one for CDA, are vital in ensuring that urgently needed medicines are made available as quickly and safely as possible."


'"/>


15-Nov-2005


Page: 1 2

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Research milestone brings goal closer of cheap antimalarial drug for developing world
3. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World
4. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
5. New study suggests promising drug combinations for sleeping sickness
6. Recombination protein dynamics observed with single monomer resolution
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New combination treatment induces regression of prostate cancer
9. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
10. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
11. Pesticide combinations imperil frogs, probably contribute to amphibian decline

Post Your Comments:
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
(Date:4/16/2015)... Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) annual ... the Pennsylvania Convention Center, starting Saturday, April 18, in ... AACR holds claim to title of the oldest and ... journals, provides fellowships and grants, and partners with survivors ...
(Date:4/16/2015)...  In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Superdome and Denver,s Coors Field ... 17, and coincide with hemophilia community events in a dozen ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
(Date:4/16/2015)... 2015 Avelas Biosciences, an in vivo ... announced today that it has initiated a Phase 1b ... women with primary, non-recurrent breast cancer undergoing surgery. In ... addition of Steven Chen , M.D., as vice ... dose escalation study will enroll up to 39 women ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
Cached News: